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Abstract Retinoic acid receptor-related orphan receptor-K
(RORK) is a nuclear orphan receptor. Adenovirus-mediated
overexpression of RORK1 and RORK4 suppressed tumor ne-
crosis factor-K (TNF-K)-induced expression of vascular cell ad-
hesion molecule-1 (VCAM-1) and intracellular adhesion mole-
cule-1 (ICAM-1) in human umbilical vein endothelial cells.
Overexpression of RORK1 and RORK4 also suppressed TNF-
K-stimulated translocation of p50 and p65 to the nucleus. In
contrast, dominant-negative deletion mutants of RORK1 and
RORK4 failed to suppress the induction of VCAM-1 and
ICAM-1 and translocations of p50 and p65. These results sug-
gest that RORK1 and RORK4 regulate the in£ammatory re-
sponses via inhibition of the nuclear factor-UB signaling path-
way in endothelial cells.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Endothelial cells (ECs) are stimulated by pro-in£ammatory
cytokines such as tumor necrosis factor-K (TNF-K) and IL-6
to express adhesion molecules for leukocytes and other in-
£ammatory cells such as vascular cell adhesion molecule-1
(VCAM-1) and intracellular adhesion molecule-1 (ICAM-1)
[1,2]. Increased expression of adhesion molecules on ECs leads
to leukocyte recruitment via interactions with their cognate
ligands on leukocytes at the sites of atherosclerosis [3,4].
The VCAM-1 and ICAM-1 promoters contain binding sites
for two major transcription factors, nuclear factor-UB (NF-
UB) and activator protein-1 (AP-1) [5^8]. NF-UB is an induc-
ible dimeric transcription factor of the Rel/NF-UB family [9],
and activated NF-UB is present in atherosclerotic lesions [10].
It is involved in the regulation of several pro-in£ammatory
genes in ECs [11]. AP-1 proteins are dimers of Jun and Fos
family members [12] and are regulated by growth factors,
cytokines, and oxidative stress [13]. Thus, NF-UB and AP-1
both play roles in regulating the in£ammatory response in
vasculature.
Recently, activators of nuclear receptors, such as the estro-
gen receptor, glucocorticoid receptor, retinoid receptor, and
peroxisome proliferator-activated receptor (PPAR) [14^18],
have been shown to inhibit the expression of several adhesion
molecules in vascular cells, possibly mediated by inhibiting the
NF-UB signaling pathway and/or AP-1 signaling pathway.
Therefore, it has been suggested that nuclear receptors have
a potential role in modulating pro-in£ammatory gene expres-
sion at in£ammatory sites in the vascular wall during athero-
sclerosis and other in£ammatory diseases.
Retinoic acid receptor-related orphan receptor (ROR) be-
longs to the steroid hormone nuclear receptor superfamily
[19]. There are three ROR genes, RORK, RORL, and
RORQ. The human RORK gene encodes at least four distinct
splicing isoforms, RORK1, RORK2, RORK3, and RORK4
(also termed RZRK) [20^22]. These isoforms share common
DNA-binding domains (DBDs) and putative ligand-binding
domains (LBDs), but di¡er in their N-terminal domains.
RORK usually binds as a monomer to a ROR response ele-
ment (RORE) composed of a 6 bp A/T-rich sequence imme-
diately preceding a site with the core motif of RGGTCA
(R=A or G) [21]. The four isoforms of RORK display di¡er-
ent binding preferences and transcriptional activities. Stagger-
er mice, whose RORK gene has a deletion in the RORK LBD
sequence causing a frame shift in the protein, are character-
ized by severe cerebella ataxia due to a developmental defect
in Purkinje cells [23]. The mice have an increased susceptibility
to atherosclerosis [24] and show alterations in several immune
responses [25]. Recently it was reported that RORK sup-
pressed TNF-K-induced expression of COX-2, IL-6, and IL-
8 in vascular smooth muscle cells (VSMCs) in part by upreg-
ulating IUBK gene expression [26]. Furthermore RORK ex-
pression in atherosclerotic plaque was found to be signi¢-
cantly decreased [27]. Therefore, RORK may play an
important role in modulating in£ammatory responses in vas-
culature. There is little information, however, about the e¡ects
of RORK on vascular ECs. In this study, we show that
RORK1 and RORK4 are present in human umbilical vein
endothelial cells (HUVECs) and that adenovirus-mediated
overexpression of RORK1 and RORK4 suppresses TNF-K-
induced expression of VCAM-1 and ICAM-1 via inhibiting
NF-UB activation thus regulating the in£ammatory response.
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2. Materials and methods
2.1. Cells and materials
HUVECs (Clonetics, San Diego, CA, USA) were maintained in
EBM-2 Bullet Kit (Clonetics). CV-1 cells (ATCC CCL-70) were cul-
tured with Eagle’s minimum essential medium containing 10% fetal
bovine serum and non-essential amino acids. TNF-K was purchased
from RpD Systems (Abingdon, UK).
2.2. Adenovius generation and infection
RORK1 and RORK4 cDNA were cloned from human fetal liver
(Human Quick-Clone cDNA, Clontech, Palo Alto, CA, USA) and
inserted into the vector, pcDNA (Invitrogen, Carlsbad, CA, USA).
RORK1v and RORK4v were constructed by deleting the fragment
between the NcoI site and the C-terminal end and inserted into the
pcDNAvector. Recombinant adenoviruses (Ad-RORK1, Ad-RORK1v,
Ad-RORK4, and Ad-RORK4v) were constructed with the Adeno-X
Expression System (Clontech) according to the manufacturer’s in-
structions. Ad-lacZ (Clontech) was used as the control in each experi-
ment. HUVECs were infected with these adenoviruses at a multiplicity
of infection of 100.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated from HUVECs with the RNeasy Mini Kit
(Qiagen, Hilden, Germany). RT-PCR analysis was performed with 15
ng total RNA and the GeneAmpEZ rTth RNA PCR Kit (Applied
Biosystems, Foster, CA, USA). The speci¢c primer sets for the target
genes were as follows: for RORK1, 5P-ACCCCGCTGAACCAGGA-
ATC-3P and 5P-GAAGTTCCGTCAGCCCGTTG-3P (505 bp prod-
ucts); for RORK2, 5P-CCTGGAGGCAGAATGGCAAG-3P and 5P-
CCGTTGGCCGAGATGTTGTA-3P (451 bp); for RORK3, 5P-AA-
CTGGGATGGAGCCACAGC-3P and 5P-CCGTTGGCCGAGATG-
TTGTA-3P (445 bp); for RORK4, 5P-CTCCGCACCGCGCTTAAT-
3P and 5P-GAAGTTCCGTCAGCCCGTTG-3P (441 bp); for RORK-
LBD, 5P-CAGAGTGTGCCGTGCCTTTG-3P and 5P-TCAATTTG-
CATTGCTGGCTCA-3 (468 bp). RT-PCR was carried out by incu-
bating the reaction mixture for 30 min at 60‡C and 60 s at 94‡C,
followed by 35 cycles of 15 s at 94‡C and 15 s at 60‡C. The RT-
PCR products were analyzed by electrophoresis in a 2.5% agarose gel
followed by ethidium bromide staining.
Quantitative real-time RT-PCR was performed with 15 ng total
RNA, the QuantiTect SYBR Green RT-PCR Kit (Qiagen), and the
speci¢c primer sets for the target genes were as follows: for VCAM-1,
5P-TGGGCTGTGAATCCCCATCT-3P and 5P-GGGTCAGCGCGT-
GGAATTGGTC-3P ; for ICAM-1, 5P-CGTGGGGAGAAGGAGCT-
GAA-3P and 5P-CAGTGCGGCACGAGAAATTG-3; for IUBK, 5P-
CCTGCAGCAGACTCCACTCC-3P and 5P-CAGGCAGCCCTGCT-
CACAG-3P. RT-PCR was carried out by incubating the reaction mix-
ture for 30 min at 60‡C and 15 min at 95‡C, followed by 40 cycles of
15 s at 94‡C, 30 s at 58‡C, and 30 s at 72‡C. GAPDH mRNA levels
were measured with TaqMan EZ RT-PCR Kit (Applied Biosystems)
and Pre-Developed TaqMan Assay Reagents Control Kit (Applied
Biosystems). The mRNA expression levels were normalized by
GAPDH expression and presented as the relative expression level
compared to the expression levels obtained from the Ad-lacZ control.
2.4. Transcriptional assay
CV-1 cells were transfected using 4 Wl of FuGENE6 (Roche, Basel,
Switzerland), with 1 Wg pTK-RORE-Luc plasmid, which contained a
thymidine kinase promoter controlling the expression of luciferase
with RORE (4 tandem copies of TCGCAAAATGGGTCACGG),
mixed with 0.1^0.3 Wg of pcDNA encoding RORK1, RORK1v,
RORK4, or RORK4v. The transfected cells were cultured in Eagle’s
minimum essential medium containing 2% charcoal/dextran-treated
fetal bovine serum (Hyclone, Logan, UT, USA) and non-essential
amino acids. Luciferase activity was measured after incubation for
48 h (Dual Luciferase Assay Kit, Promega, Madison, WI, USA). In
the experiments, 0.05 Wg pRL-TK (Renilla luciferase reporter, Prom-
ega) was included in the transfection mixture, and the promoter-de-
pendent transcriptional activity was normalized to Renilla luciferase
activity.
2.5. Western blot analysis
Cytoplasmic and nuclear extracts were prepared from HUVECs
using CellLyticNu-CLEAR Extraction Kit (Sigma, St. Louis, MO,
USA). The extracts (cytoplasmic protein, 2.5 Wg; nuclear protein, 10
Wg) were analyzed by Western blot analysis using the speci¢c antibody
against RORK (sc-6062), VCAM-1 (sc-13160), ICAM-1 (sc-8439),
NF-UB p50 (sc-8414), NF-UB p65 (sc8008), IUBK (sc-1643), Jun (sc-
45), or phosphorylated Jun (sc-7981) (all from Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and detected by chemiluminescence.
2.6. Statistical analysis
Quantitative data were expressed as meansUS.D. from three or
four experiments. Statistical analysis was performed using the
ANOVA program, and probability values were calculated using the
Dunnet test. A value of P6 0.05 was considered signi¢cant.
3. Results
3.1. Speci¢c RORK isoforms are expressed in HUVECs
We ¢rst investigated whether RORK is expressed in human
ECs and if so, which of the four RORK isoforms was present.
Using speci¢c primers for RORK isoforms, we determined
that RORK1 and RORK4 were expressed in HUVECs by
RT-PCR (Fig. 1A). In contrast, expression of both RORK2
and RORK3 was undetectable, even if the input of RNA or
number of PCR cycles was increased. These results show that
RORK1 and RORK4 were the main transcripts of the RORK
gene in HUVECs.
Fig. 1. A: RORK1 and RORK4 are expressed in HUVECs. Total
RNA was analyzed by RT-PCR as described. B: Schematic repre-
sentation of RORK1, RORK4, and their deletion mutants, RORK1v
and RORK4v. The black triangle indicates the start of the deletion
of RORK transcripts from Staggerer mice. C,D: RORK1 and
RORK4 activate the RORE-dependent transcription. CV-1 cells
were co-transfected with the pTK-RORE-Luc plasmid (1 Wg), pRL-
TK (0.05 Wg) and pcDNA and/or pcDNA encoding RORK1,
RORK4, RORK1v, or RORK4v as indicated. The results are pre-
sented as fold induction of the basal activity of pcDNA.
***P6 0.001 versus pcDNA.
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3.2. The transactivation activities of RORK1 and RORK4 are
mediated by their LBDs
To test the functionality of cloned RORK1 and RORK4, we
analyzed the ability of RORK1 and RORK4 to transcribe a
luciferase reporter plasmid, in which the promoter contains
RORE (4U) whose speci¢c sequence was derived from the
promoter of 5-lipoxygenase [28]. Co-transfection in CV-1 cells
of the reporter plasmid and the expression vector containing
RORK1 led to RORE-dependent luciferase activity (Fig. 1C).
In contrast, when the RORK4 expression vector was co-trans-
fected with the luciferase reporter plasmid, there was an in-
crease of only two-fold at the highest plasmid concentration in
luciferase activity. These data are consistent with previous
results [21,22], in which it was shown that RORK1 promoted
RORE-dependent transcription but the e¡ect of RORK4 was
much weaker. To demonstrate that this was speci¢c transcrip-
tion due to RORK, we next constructed two expression plas-
mids encoding mutant RORK, RORK1v and RORK4v, in
which their LBDs were deleted (Fig. 1B). The mutations are
functionally equivalent to the deletion mutation that occurs in
the Staggerer mouse, in which RORK has been shown to be
inactive as a transcription factor [23]. Co-transfection of ei-
ther RORK1v or RORK4v with a luciferase reporter plasmid
shows that these mutants have lost their transcriptional activ-
ity and cannot transcribe luciferase (Fig. 1D). Our results
indicate that both RORK1v and RORK4v require the LBD
for their transactivation activity.
3.3. The dominant-negative e¡ect of RORK1v or RORK4v
Furthermore, we found that co-transfection of RORK1 with
either RORK1v or RORK4v and the luciferase reporter plas-
mid into CV-1 cells attenuated the RORK1-dependent tran-
scriptional activity (Fig. 1D). These results indicated that
RORK1v and RORK4v acted as dominant-negative forms
able to inhibit the activity of RORK1. Thus RORK1v and
RORK4v are excellent tools to investigate RORK function
in human ECs.
3.4. RORK1 and RORK4 suppress VCAM-1 and ICAM-1
expression induced by TNF-K in HUVECs
Since RORK1 and RORK4 were the major isoforms of
RORK present in HUVECs, we next examined whether
RORK1 and RORK4 could regulate pro-in£ammatory genes.
Because of the di⁄culties in transfecting primary ECs with
plasmids, we developed recombinant adenoviruses that en-
coded RORK1 and RORK4 as well as their deletion mutants,
RORK1v and RORK4v. At 24 h after infection with Ad-lacZ,
almost all of the HUVECs were expressing L-gal (data not
shown). Expression of RORK1 and RORK4 protein in HU-
VECs was detected by Western blotting analysis with an anti-
body directed against the C-terminal region of RORK allow-
ing detection of all isoforms of RORK but not RORK1v and
RORK4v (Fig. 2A). However, RT-PCR analysis indicated
that they were expressed in HUVECs (Fig. 2B).
We then analyzed the expression of VCAM-1 and ICAM-1
by quantitative real-time RT-PCR. VCAM-1 and ICAM-1
expression were highly induced by 1 ng/ml TNF-K treatment
for 6 h (VCAM-1: 1100-fold, ICAM-1: 170-fold; Fig. 3A,B).
We found that TNF-K-induced VCAM-1 expression was com-
pletely suppressed by infection with Ad-RORK1 (99.8% re-
duction compared to TNF-K-stimulated Ad-lacZ; Fig. 3A).
VCAM-1 induction was reduced in Ad-RORK4-infected HU-
VECs (73% reduction). In contrast, Ad-RORK1v and Ad-
RORK4v failed to suppress the induction of VCAM-1. As
shown in Fig. 3B, Ad-RORK1 also suppressed TNF-K-in-
duced ICAM-1 expression in HUVECs (74% reduction), but
Ad-RORK4 was slightly less e¡ective in reducing ICAM-1
induction (49% reduction). The levels of VCAM-1 and
ICAM-1 protein expression were con¢rmed by Western blot-
ting analysis (Fig. 3C). These data indicate that the presence
of RORK1 or RORK4 can prevent the TNF-K-induced ex-
pression of VCAM-1 and ICAM-1 in HUVECs, but that their
dominant-negative mutants could not suppress the induction
of VCAM-1 and ICAM-1.
3.5. The suppression of VCAM-1 and ICAM-1 expression by
RORK is mediated by inhibiting nuclear translocation of
p50/p65
To determine the mechanisms by which RORK1 and
RORK4 inhibited TNF-K-induced VCAM-1 and ICAM-1 ex-
pression, we examined whether RORK could inhibit NF-UB
activation. NF-UB is composed of the p50 and p65 subunits
and translocation of the complex to the nucleus is one of the
critical steps in activating the NF-UB signaling pathway. As
Fig. 2. Adenovius-mediated gene expression of RORK1 and RORK4
in HUVECs. HUVECs were infected with the recombinant adenovi-
ruses and cultured for 24 h. Western blotting analysis was per-
formed on the nuclear extracts (A) and RT-PCR analysis was pre-
formed on the total RNA (B) as described. Z, Ad-lacZ; K1, Ad-
RORK1; K1v, Ad-RORK1v ; K4, Ad-RORK4; K4v, Ad-RORK4v.
Fig. 3. RORK1 and RORK4 inhibit TNF-K-induced expression of
VCAM-1 and ICAM-1 in HUVECs. HUVECs were infected with
the recombinant adenoviruses and cultured for 18 h. Total RNA
was prepared after treatment with 1 ng/ml TNF-K for 6 h, and ana-
lyzed by quantitative real-time RT-PCR as described. The normal-
ized expression of VCAM-1 (A) and ICAM-1 (B) by GAPDH is
presented as the relative expression to their basal expression in Ad-
lacZ-infected and unstimulated cells. **P6 0.01, ***P6 0.001 versus
Ad-lacZ. C: The cytoplasmic extracts of the HUVECs were pre-
pared and then VCAM-1 and ICAM-1 were detected with speci¢c
antibodies.
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expected, TNF-K treatment increased the nuclear abundance
of p50 and p65 in HUVECs (Fig. 4) and this translocation
was clearly suppressed by overexpression of RORK1 or
RORK4. In contrast, Ad-RORK1v and Ad-RORK4v failed
to suppress the translocation of p50 and p65 to the nucleus.
The retention of p50 and p65 in the cytoplasm was not
changed whichever form of RORK was overexpressed. There-
fore, these data indicate that RORK1 and RORK4, but not
their dominant-negative deletion mutants, inhibited NF-UB
signal activation without regulating p50 and p65 protein ex-
pression.
3.6. Inhibition of p50/p65 nuclear translocation by RORK
overexpression is not mediated by upregulating IUBK
expression
It has been suggested that the anti-in£ammatory e¡ect of
RORK is mediated by upregulation of IUBK expression in
VSMCs [26]. To test this, we then determined whether
RORK1 and RORK4 could upregulate IUBK expression in
ECs. In unstimulated cells, IUBK complexes with NF-UB
and inhibits the translocation of NF-UB to the nucleus. We
analyzed the expression levels of IUBK by quantitative real-
time RT-PCR and Western blot analysis. Fig. 5 shows that
IUBK mRNA expression in HUVECs was upregulated 11-fold
by TNF-K treatment for 6 h. Surprisingly, RORK1 and
RORK4 clearly repressed both TNF-K-induced IUBK mRNA
(RORK1, 78% reduction; RORK4, 79% reduction) and IUBK
protein. In contrast, overexpression of either RORK1v or
RORKv did not reduce the expression of IUBK mRNA and
protein induced by TNF-K. Therefore, in contrast to the pre-
vious observations in VSMCs, these results indicated that
RORK1 and RORK4 negatively regulated TNF-K-induced
IUBK expression.
3.7. RORK1 reduces phosphorylation and translocation of
c-Jun
Since the expression of VCAM-1 and ICAM-1 are regu-
lated not only by NF-UB but also by another transcriptional
factor, AP-1 [6,8], we tested the e¡ect of RORK overexpres-
sion on AP-1 activation. AP-1 protein is a dimer of the Jun
and Fos families, and its transcription activity is correlated
with the translocation and phosphorylation of c-Jun at Ser 63
and Ser 73 by the Jun-N-terminal kinase [29]. Overexpression
of RORK1, but not RORK4, in HUVECs by adenovirus vec-
tors decreased c-Jun protein contents in the nucleus (Fig. 4).
Furthermore, the overexpression reduced c-Jun phosphoryla-
tion at Ser 73 (Fig. 4). As expected, RORK1v and RORK4v
had no e¡ect on the nuclear abundance and the phosphory-
lation of c-Jun. Thus, these data suggest that RORK1 sup-
pressed not only the NF-UB signaling pathway but also the
AP-1 signaling pathway.
4. Discussion
Several studies have indicated that nuclear receptors includ-
ing estrogen receptor, glucocorticoid receptor, retinoid recep-
tor, and PPAR, inhibit the expression of genes involved in the
in£ammatory response in vascular cells [14^18]. In contrast,
the e¡ect of RORK on expression of these genes in vascular
cells has been poorly studied, and, in particular, the role of
RORK on expression of adhesion molecules has not been
described. RORK1 can activate the expression of genes, which
have a RORE in their promoter region, and while RORK4
can also bind the same sequences its activity is much weaker
than that of RORK1. Recently, Besnard et al. [27] found that
human aortic VSMCs and ECs expressed RORK1 and
RORK4 but did not express RORK2 and RORK3. In this
report, we have con¢rmed the presence of RORK1 and
RORK4 in HUVECs, which suggests RORK, and, in partic-
ular, RORK1 might play a role in modulating gene expression
in vascular cells.
The adhesion molecules VCAM-1 and ICAM-1 are highly
regulated at the transcriptional level by a number of media-
tors, such as TNF-K [6,7]. Recent promoter studies have char-
acterized the 5P regulatory region of VCAM-1 and ICAM-1.
TNF-K induces binding of NF-UB to the promoter region of
VCAM-1 and ICAM-1 [5,7]. By adenovirus-mediated gene
transfer of RORK1 and RORK4, we showed that overexpres-
sion of RORK1 and RORK4 downregulated TNF-K-induced
VCAM-1 and ICAM-1 expression in HUVECs. In contrast,
overexpression of their deletion mutants of LBD did not
downregulate the induction of VCAM-1 and ICAM-1. The
inhibitory e¡ects of these RORK proteins correlate with their
transcriptional activities determined on a luciferase reporter
gene (Fig. 1C). This is the ¢rst report demonstrating that
RORK regulates the expression of adhesion molecules in
ECs and that the LBD is necessary for their regulation.
We then investigated the role of the NF-UB system in con-
Fig. 5. RORK1 and RORK4 inhibit TNF-K-induced IUBK expres-
sion in HUVECs. HUVECs were treated as described in Fig. 3.
Quantitative real-time RT-PCR analysis (A) and Western blot anal-
ysis (B) were performed. ***P6 0.001 versus Ad-lacZ-infected and
TNF-K-treated cells.
Fig. 4. RORK1 and RORK4 suppress TNF-K-induced translocation
of p50, p65, and c-Jun in HUVECs. HUVECs were treated as de-
scribed in Fig. 3, and then cytoplasmic and nuclear extracts were
prepared. p50, p65, c-Jun, and phosphorylated c-Jun were detected
with speci¢c antibodies.
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trolling the TNF-K induction of the adhesion molecules and
showed that overexpression of RORK1 and RORK4 nega-
tively regulated the TNF-K-stimulated translocation of p50
and p65 into the nucleus. Recently, Delerive et al. [26] re-
ported that RORK1 suppressed TNF-K-induced IL-6, IL-8,
and COX-2 expression in VSMCs. They suggested that the
mechanism of action was mediated via the transcriptional up-
regulation of IUBK by RORK1. In contrast to their ¢ndings,
we demonstrated that RORK1 downregulated TNF-K-induced
IUBK expression. In addition, we observed that overexpression
of RORK1 and RORK4 did not upregulate the basal expres-
sion of IUBK but we con¢rmed that RORK1 and RORK4
overexpression suppressed TNF-K-induced expression of oth-
er NF-UB-regulated genes such as IL-6 and COX-2, in HU-
VECs (data not shown). The suppression of these in£amma-
tory response genes is clearly due to inhibition of p50 and p65
nuclear translocation. Therefore, our data con¢rm Delerive et
al.’s data [26] that RORK1 negatively regulates the in£amma-
tory response. However, the regulation in ECs treated with
TNF-K was not due to transcriptional upregulation of IUBK
expression. It is known that IUBK is not only an inhibitor of
NF-UB but also its expression is modulated by NF-UB [9]. The
promoter region of IUBK has a NF-UB binding site. TNF-K
treatment increases IUBK expression via NF-UB activation
[30]. Our data con¢rm that TNF-K treatment upregulates
IUBK but that RORK1 and RORK4 overexpression does not
upregulate IUBK. Furthermore, RORK1 and RORK4 suppress
TNF-K-induced IUBK upregulation in ECs. It is possible that
NF-UB activation by TNF-K was quickly suppressed by
RORK and in consequence IUBK upregulation was prevented.
Alternatively, other negative regulatory element may exist in
the IkBK promoter region. Our results clearly show that vas-
cular ECs RORK1 and RORK4 inhibit NF-UB-induced gene
expression and that the inhibition is not due to upregulation
of IUBK expression levels. Rather, the inhibition of NF-UB
activation may result from inhibition of IUBK phosphoryla-
tion and/or degradation.
AP-1 is a family of transcriptional factors composed of
various dimers of Jun (c-Jun, JunB, and JunD) and Fos (c-
Fos, FosB, Fra-1, and Fra-2) [14]. These family members bind
to DNA containing a TPA (12-O-tetradecanoyl-phorbol-13-
acetate)-responsive element to regulate gene expression. AP-
1 responds to a variety of pathological stimuli, and TNF-K
stimuli lead to AP-1 activation and induce VCAM-1 and
ICAM-1 expression [6,8]. We demonstrated that RORK1 sup-
pressed the translocation and the phosphorylation of c-Jun in
HUVECs. This report shows that RORK1 inhibits AP-1 acti-
vation, suggesting that it may have the potential to suppress
the e¡ects of many pathological stimuli.
In this report, we describe mechanisms by which the NF-UB
signaling pathway is inhibited by RORK1 and RORK4.
RORK could regulate the signaling pathway in two ways.
First, through their transcription activity, RORK1 and
RORK4 may regulate an inhibitory molecule(s) of NF-UB.
RORK1 stimulates RORE-dependent transcriptional activity
and RORK4 weakly activates transactivation. In addition, the
LBD-deletion mutants of RORK1 and RORK4 failed to stim-
ulate transcriptional activity, to suppress gene expression, and
to translocate p50 and p65. Thus their LBDs are essential for
both their transactivation and translocation activity. The reg-
ulation of the NF-UB signaling pathway by RORK1 and
RORK4 may correspond to the levels of their transcription
activity (RORK1sRORK4ERORKv). Thus it is plausible
that RORK regulates an inhibitory molecule(s) of the NF-
UB signaling pathway. The inhibitor could be a molecule
that blocks the activity of either RIP, TRAF1 or 2, TAK1,
IKK, or blocks IUB degradation through upregulation of IUB
expression, inhibition of IUB phosphorylation, inhibition of
IUB ubiquitination or inhibition of the proteosome. We report
in this manuscript that IUBK expression is not upregulated by
RORK. We also found that RORK did not change the expres-
sion level of IKKL (data not shown). It would be of interest
to explore further which molecule is responsible for inhibiting
NF-UB activity mediated by RORK. Second, RORK may reg-
ulate NF-UB signaling pathway through the LBD of RORK
independently of its transactivation activity by a mechanism
such as direct interaction of p50/p65 with RORK. We have
shown that the LBD is essential for p50/p65 nuclear trans-
location (Fig. 4). Analogously, PPARK physically interacts
with p65 and c-Jun [31] and PPARQ also bound p50 and
p65 [32]. These reports suggest that the interference with
NF-UB transactivation by PPAR might involve the direct
binding to p50/p65. Nuclear receptors including retinoic acid
receptor and Rev-erb, which are closely homologous to
RORK, have been reported to have a nuclear location signal
within DBD [33]. It is not known whether RORK also has a
nuclear location signal within the DBD. Regardless, we can-
not exclude the possibility that the LBD deletion mutant may
be retained in the cytoplasm. In that case, the ROR mutant
may lose transactivation activity due to a defect in nuclear
translocation. We have shown loss of function of the deletion
mutant (Fig. 1C). However, the deletion mutant that was
retained in the cytoplasm would not antagonize wild-type
RORK1. We have shown a dominant-negative e¡ect in Fig.
1D, suggesting that the deletion mutant was expressed and
translocated into the nucleus where it competed with the
wild-type RORK1 for RORE binding. Thus, we believe that
there is strong circumstantial evidence that RORK1v and
RORK4v are translocated to the nucleus. Further insight
into the inhibition mechanisms of the interaction of RORK
with p50/p65 warrants investigation.
In conclusion, our study demonstrates that overexpression
of RORK1 and RORK4 inhibits TNF-K-induced expression of
VCAM-1 and ICAM-1 in HUVECs by inhibiting the NF-UB
signaling pathway. These results provide insights into the role
that RORK plays in regulation of in£ammatory response in
vascular ECs.
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